[PDF] Top 20 Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
Has 10000 "Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes" found on our website. Below are the top 20 most common "Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes".
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
... with tofacitinib was associated with statistically significant dose-dependent improvement in HRQoL and patient preference for the study ...clinical efficacy and safety data pre- viously ... See full document
10
The efficacy of tourniquet assisted total knee arthroplasty on patient reported and performance based physical function: a randomized controlled trial protocol
... superiority trial, with balanced randomization ...on patient-reported physical function ...explorative outcomes include; use of pain medication, single-fiber muscle damage, and changes in ... See full document
10
Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
... UNIFI trial was presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2018 ...III trial was a double-blind, randomized placebo-controlled, multi-center, with a single ... See full document
6
Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary
... UC based on biopsy, baseline endos- copy was not required for participation in the ...experiencing active inflammation of the colon or rectal mucosa at the time of their ...clinical trial, precluding ... See full document
9
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
... quantitative analysis of mucosal inflammation: .50 µ g/g demonstrated active inflammation and ...no reported dose response in remission or clinical response based on the ...and efficacy ... See full document
8
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
... and patient-reported outcomes were analyzed in the intention-to-treat population (all randomized patients), and safety was analyzed in all patients who received at least one dose of study ... See full document
11
<p>Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy</p>
... Given tofacitinib ’ s effects on in fl ammatory signaling, test- ing in Crohn ’ s disease was also evaluated via three multi- center, randomized, double-blind, placebo-controlled Phase II clinical ...were ... See full document
13
Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta analysis and economic evaluation
... and active disease. Because of the way trial data were often reported, it was not always possible to derive transi- tion probabilities for maintaining response or remission, conditional on the ... See full document
13
Effects of tofacitinib monotherapy on patient reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
... 3 trial, DMARD-IR patients receiving tofacitinib 5 and 10 mg BID monotherapy reported statistically significant and clinically meaningful improve- ments in PtGA, Pain, HAQ-DI, HRQoL, and fatigue at 3 ... See full document
12
Effect of tofacitinib on patient reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
... (A) patient-reported outcomes (PROs), (B) Short Form-36 Health Survey version 2 (SF-36v2) domain scores; and percentages of patients reporting scores ≥normative values in (C) PROs; (D) SF-36v2 domain ... See full document
11
<p>Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data</p>
... of tofacitinib in the induction of remission in patients with moderately-to-severely active UC was inves- tigated in two multi-center, double-blind, placebo- controlled phase 3 trials, named OCTAVE (Oral ... See full document
15
Relationship between clinical and patient reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX naïve patients with rheumatoid arthritis
... and patient- reported Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (by visual analogue scale) and patient global assessment of disease activity (PtGA) as components of the ACR ... See full document
9
Drugs in development for prophylaxis of rejection in kidney-transplant recipients
... At 3 years, a total of 471 patients had completed $3 years of therapy (158 MI, 170 LI, 143 CsA). A total of 92% MI, 92% LI, and 89% CsA patients survived with a functioning graft. Belatacept-treated patients continued to ... See full document
11
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
... this trial examined 459 patients and randomized them to receive either MMX mesalamine ...ned based on the outcomes from the prior parent ... See full document
6
Tofacitinib versus methotrexate in rheumatoid arthritis: patient reported outcomes from the randomised phase III ORAL Start trial
... was based on the full ana- lysis set (FAS; all patients who received ≥ 1 dose of study drug and with ≥ 1 postbaseline ...between tofacitinib and MTX treatment groups using the normal approximation to the ... See full document
11
Nutritional support and dietary interventions for patients with ulcerative colitis: current insights
... Abstract: Ulcerative colitis (UC) demonstrates a remitting and relapsing course, and patients have long believed diet plays a role in their ...treatment efficacy lies in modification of dietary ... See full document
9
Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
... is reported most often within the first 12 months, but also delayed presentation after several years has been ...treatment reported in the literature, and the absence of a clear relationship between 5-ASA ... See full document
15
Sushma M Shridhara BS, Shaila borannavar .......
... practice. Ulcerative colitis is the most common among ...on Ulcerative Colitis based on Samshodhana Karma, in which 40 years old female patient suffering from Ulcerative ... See full document
6
Patient considerations in the management of ulcerative colitis – role of vedolizumab
... The patient was hospitalized, and serological testing for HIV, Epstein-Barr virus, cytomegalovirus, and hepatitis was ...The patient was treated symptomatically with IV hydration and pain management with ... See full document
8
<p>Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives</p>
... double-blind, active- controlled and placebo-controlled, phase 3 trial investigating the ef fi cacy of tofacitinib compared to placebo or adalimu- mab in patients with active PsA with an ... See full document
11
Related subjects